Skip to main content

Table 3 Expression analysis of genes involved in base-excision repair

From: The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale)

 

APE1

Median (range)

PARP1

Median (range)

XRCC1

Median (range)

Stable disease/Partial response

(n = 7)

32.45 (0.01–176.7)

0.5 (0.001–2.63)

0.2 (0.008–1.05)

Progression

(n = 7)

47.18 (4.48–87.73)

1.36 (0.01–26.17)

0.58 (0.04–1.26)

  1. Data are expressed as relative log2 expression